Altimmune, a Maryland-based biopharma, is collaborating with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine, AdCOVID.
AdCOVID is a single-dose, intranasal vaccine candidate designed to protect against COVID-19, the disease caused by the SARS-CoV-2 virus.
In response to the global pandemic, Altimmune has created a COVID-19 vaccine candidate and is currently preparing for immunogenicity studies and manufacture of Phase 1 clinical trial material.
Initially, Altimmune will work with UAB investigators on preclinical animal studies and characterisation of the vaccine immunogenicity with the goal of enabling a Phase 1 trial in Q3 of this year.
Six UAB labs will work together on this urgent collaboration with Altimmune.